首页> 美国卫生研究院文献>other >Biodegradable Gelatin Microparticles as Delivery Systems for the Controlled Release of Bone Morphogenetic Protein-2
【2h】

Biodegradable Gelatin Microparticles as Delivery Systems for the Controlled Release of Bone Morphogenetic Protein-2

机译:可生物降解的明胶微粒作为控制释放骨形态发生蛋白2的传递系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This work evaluated gelatin microparticles and biodegradable composite scaffolds for the controlled release of bone morphogenetic protein-2 (BMP-2) in vitro and in vivo. Gelatin crosslinking (10 and 40 mM glutaraldehyde), BMP-2 dose (6 and 60 ng BMP-2 / mg dry microparticles), buffer type (phosphate buffered saline (PBS) and collagenase-containing PBS), and gelatin type (acidic and basic) were investigated for their effects on BMP-2 release. Release profiles were also observed using poly(lactic-co-glycolic acid) (PLGA) microparticles with varying molecular weights (8,300 and 57,500). In vitro and in vivo studies were conducted using radiolabeled BMP-2; the chloramine-T method was preferred over Bolton-Hunter reagent for radioiodination with this system. BMP-2 release from PLGA microparticles resulted in a moderate burst release followed by minimal cumulative release, while BMP-2 release from gelatin microparticles exhibited minimal burst release followed by linear release kinetics in vitro. Growth factor dose had a small effect on its normalized release kinetics probably because of an equilibrium between gelatin-bound and unbound BMP-2. Differences in release from acidic and basic gelatin microparticles may result from the different pretreatment conditions used for gelatin synthesis. The in vitro release kinetics for both gelatin microparticles alone and within composite scaffolds were dependent largely on the extent of gelatin crosslinking; varying buffer type served to confirm that controlled release relies on enzymatic degradation of the gelatin for controlled release. Finally, in vivo studies with composite scaffolds exhibited minimal burst and linear release up to 28 days. In summary, dose effects on BMP-2 release were found to be minimal while varying gelatin type and release medium can alter release kinetics. These results demonstrate a systematic control of BMP-2 delivery from gelatin microparticles can be achieved by altering the extent of basic gelatin crosslinking.
机译:这项工作评估了明胶微粒和可生物降解的复合支架在体外和体内对骨形态发生蛋白2(BMP-2)的控制释放。明胶交联(10和40 mM戊二醛),BMP-2剂量(6和60 ng BMP-2 / mg干微粒),缓冲液类型(磷酸盐缓冲盐水(PBS)和含胶原酶的PBS)和明胶类型(酸性和酸性) (基础)对它们对BMP-2释放的影响进行了研究。使用具有不同分子量(8,300和57,500)的聚乳酸-乙醇酸共聚物(PLGA)微粒也观察到了释放曲线。使用放射性标记的BMP-2进行了体外和体内研究;对于该系统的放射性碘化,氯胺-T方法优于Bolton-Hunter试剂。从PLGA微粒释放的BMP-2导致中等程度的突释释放,然后是最小的累积释放,而从明胶微粒释放的BMP-2表现出最小的突释释放,然后在体外呈线性释放动力学。生长因子剂量对其归一化释放动力学的影响很小,这可能是由于明胶结合和未结合的BMP-2之间存在平衡。从酸性和碱性明胶微粒释放的差异可能是由于明胶合成所使用的预处理条件不同所致。明胶微粒单独和复合支架内的体外释放动力学在很大程度上取决于明胶交联的程度。改变缓冲液类型可证实控释依赖于明胶的酶促降解。最后,使用复合支架的体内研究显示长达28天的爆裂和线性释放最小。总之,发现对BMP-2释放的剂量影响最小,而明胶类型和释放介质的变化可以改变释放动力学。这些结果表明,可以通过改变碱性明胶交联程度来实现对明胶微粒中BMP-2的系统控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号